Bone cancers and other skeletal diseases can be extremely painful and cause loss of mobility, which significantly reduces quality of life. While some treatments do exist, more research is needed to find new prevention strategies and improved therapies for these diseases.
Scientists in the Skeletal Disease and Cancer Therapeutics Program study the full spectrum of bone biology, from the mechanisms that give rise to healthy bone tissue to those that cause disease, with the goal of developing new, more effective treatments. These conditions include neurofibromatosis type 1, osteoporosis, osteoarthritis, and developmental disorders in addition to bone cancers, such as Ewing sarcoma and osteosarcoma, and bone metastases.
Harlow ML*, Chassé MH*, Boguslawski EA, Sorensen KM, Gedminas MJ, Goosen JM, Rothbart SB, Taslim C, Lessnick SL, Peck A, Madaj AB, Bowman MJ, Grohar PJ. 2019. Trabectedin inhibits EWS-FLI1 and evicts SWI/SNF from chromatin in a schedule-dependent manner. Clin Cancer Res.
Vander Ark A, Li X. 2018. TGF-b receptors: in and beyond TGF- b signaling. Cell Signal 52:112–120. Lu D, Li J, Liu H, Foxa GE, Weaver K, Li J, Williams BO, Yang T. 2018. LRP1 suppresses bone resorption in mice by inhibiting the RANKL-stimulated NFκB and p38 pathways during osteoclastogenesis. J Bone Miner Res 33(10):1773–1784.
Bergsma A, Ganguly SS, Dick D, Williams BO, Miranti CK. 2018. Global deletion of tetraspanin CD82 attenuates bone growth and enhances bone marrow adipogenesis. Bone 113:105–113.
Peacock JD, Pridgeon MG, Tovar EA, Essenburg CJ, Bowman M, Madaj Z, Koeman J, Boguslawski EA, Grit J, Dodd RD, Khachaturov V, Cardona DM, Chen M, Kirsch DG, Maina F, Dono R, Winn ME, Graveel CR, Steensma MR. 2018. Genomic status of MET potentiates sensitivity to MET and MEK inhibition in NF1-related malignant peripheral nerve sheath tumors. Cancer Res 78(13):3672–3687.
Did you know?
Van Andel Institute Graduate School offers a rigorous, research-intensive Ph.D. program in molecular and cellular biology. Learn more here.